Clinical trials: Ovarian, Fallopian, and Primary Peritoneal Cancer
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent…
- Conditions
- High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- UP-NEXT (NCT05329545)
- Testing
- Upifitimab rilsodotin
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- Mersana Therapeutics
Ovarian Cancer, Peritoneal Cancer
Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
The best way to treat MBO in patients with ovarian cancer has not been studied enough by trials that assess how more than one treatment arm (surgical, chemotherapeutic, supportive care approaches) affects clinical outcomes like…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Bowel Obstruction
- Trial name
- NCT01083537
- Testing
- Cisplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with…
- Conditions
- Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
- Trial name
- NCT06682988
- Testing
- Mirvetuximab Soravtansine
- Where
- 52 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- AbbVie
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to…
- Conditions
- Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor
- Trial name
- TOASTIT (NCT04213794)
- Testing
- Cisplatin, Cytoreductive Surgery, Doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Breast Carcinoma, Deleterious CDH1 Gene Mutation
Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives
This trial collects information about factors that affect communication of genetic test results, decision-making, and access to genetic testing in women with hereditary gynecological cancers.
- Conditions
- Breast Carcinoma, Deleterious CDH1 Gene Mutation, Deleterious DICER1 Gene Mutation, Deleterious SMARCA4 Gene Mutation
- Trial name
- NCT04257045
- Testing
- Interview, Questionnaire Administration, Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Carcinoma
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
This phase I trial studies the side effects and recommended dose of the combination of p53MVA vaccine (modified vaccinia virus ankara vaccine expressing tumor protein p53 [p53]) and gemcitabine hydrochloride in treating patients…
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02275039
- Testing
- modified vaccinia virus ankara vaccine expressing p53, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well physical activity monitored by Fitbit Charge 2 works in improving quality of life in participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Ovarian Clear Cell Tumor
- Trial name
- NCT03685695
- Testing
- Laboratory Biomarker Analysis, Monitoring Device, Physical Activity
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, and total-body irradiation before a donor natural killer cell infusion helps stop the growth of tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00652899
- Testing
- Allopurinol, Cyclophosphamide, Fludarabine phosphate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This pilot clinical trial studies auranofin in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01747798
- Testing
- auranofin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan in treating patients who have advanced ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00055614
- Testing
- topotecan hydrochloride, adjuvant therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Triple Negative Breast Cancer, Breast Cancer
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Study of Emi-Le in Participants with Solid Tumors
- Conditions
- Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT05377996
- Testing
- Emi-Le
- Where
- 26 sites in United States
- Volunteers
- 360 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
This phase I trial is studying the side effects and best dose of cisplatin given together with paclitaxel in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication
- Trial name
- NCT00814086
- Testing
- Paclitaxel, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- NCT00582205
- Testing
- Paclitaxel, Cisplatin IP
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Oklahoma
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Ovarian Cancer, Fallopian Tube Cancer
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
The purpose of this study is to investigate whether the addition of the Src inhibitor saracatinib (AZD0530) to weekly paclitaxel improves efficacy, compared with paclitaxel plus placebo, in patients with relapsed…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- SaPPrOC (NCT01196741)
- Testing
- Paclitaxel, Saracatinib
- Where
- 12 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- University College, London
Ovarian Cancer
A Study of SHR-A1811 in Subjects With Ovarian Cancer
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
- Trial name
- NCT06828354
- Testing
- SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer, Fallopian Tube Carcinoma
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
- Conditions
- Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01381861
- Testing
- Carotuximab (TRC105)
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
Ovarian Cancer, Fallopian Tube Cancer
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma
Over the last few years several novel agents have been defined which are active in the treatment of relapsed epithelial ovarian carcinoma.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00157560
- Testing
- Chemotherapy, multiple agents
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Massachusetts General Hospital